Time and again, seemingly successful bank mergers have been rocked by revelations of poor anti-money-laundering compliance. Assessing the AML risk of a potential merger partner is extremely tricky, ...
Kura Oncology and Kyowa Kirin announced that clinical data from the KOMET-007 trial, evaluating ziftomenib in combination with the standard chemotherapy regimen of cytarabine and daunorubicin (7+3) ...
– 100% CR rate with 7+3 in newly diagnosed NPM1-m and KMT2A-r AML – – 56% CR/CRh with ven/aza in menin inhibitor naïve patients with R/R AML – – 80% of patients remain on trial as of data cutoff, ...
Cetera agrees to pay $1.1 million fine after FINRA found the firm failed to properly monitor suspicious penny stock transactions ...
Kura Oncology announces oral presentation of ziftomenib trial results for R/R NPM1-m AML at ASCO 2025, with investor event. Kura Oncology and Kyowa Kirin have announced that an abstract detailing the ...
NPM1-mutated AML prognosis was refined using a new genetic model integrating co-mutations, improving risk classification and ...
Kura Oncology (KURA) is in good shape with respect to its pipeline in terms of the development of its lead drug, ziftomenib, for the treatment of patients with relapsed/refractory NPM1-mutated Acute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results